Demographic Features and Clinical Course of Patients With Pediatric-Onset Multiple Sclerosis on Newer Disease-Modifying Treatments

• Published in: Pediatric neurology 2023-08, Vol.145, p.125-131
• Main Authors: Malani Shukla, Nikita, Casper, T. Charles, Ness, Jayne, Wheeler, Yolanda, Chitnis, Tanuja, Lotze, Timothy, Gorman, Mark, Benson, Leslie, Weinstock-Guttmann, Bianca, Aaen, Greg, Rodriguez, Moses, Tillema, Jan-Mendelt, Krupp, Lauren, Schreiner, Teri, Mar, Soe, Goyal, Manu, Rensel, Mary, Abrams, Aaron, Rose, John, Waltz, Michael, Liu, Tony, Manlius, Corinne, Waubant, Emmanuelle
• Format: Article
• Language: English
• Subjects: Disease-modifying treatment; Multiple sclerosis; Pediatric demyelinating disease; Pediatric multiple sclerosis
• ISSN: 0887-8994; 1873-5150
• DOI: 10.1016/j.pediatrneurol.2023.04.020

Treatment of pediatric-onset multiple sclerosis (POMS) is challenging given the lack of safety and efficacy data in the pediatric population for many of the disease-modifying treatments (DMTs) approved for use in adults with MS. Our objective was to describe the demographic features and clinical and radiologic course of patients with POMS treated with the commonly used newer DMTs within the US Network of Pediatric MS Centers (NPMSC). This is an analysis of prospectively collected data from patients who initiated treatment before age 18 with the DMTs listed below at the 12 regional pediatric MS referral centers participating in the NPMSC. One hundred sixty-eight patients on dimethyl fumarate, 96 on fingolimod, 151 on natalizumab, 166 on rituximab, and 37 on ocrelizumab met criteria for analysis. Mean age at DMT initiation ranged from 15.2 to 16.5 years. Disease duration at the time of initiation of index DMT ranged from 1.1 to 1.6 years with treatment duration of 0.9-2.0 years. Mean annualized relapse rate (ARR) in the year prior to initiating index DMT ranged from 0.4 to 1.0. Mean ARR while on index DMT ranged from 0.05 to 0.20. New T2 and enhancing lesions occurred in 75%-88% and 55%-73% of the patients, respectively, during the year prior to initiating index DMT. After initiating index DMT, new T2 and enhancing lesions occurred in 0%-46% and 11%-34% patients, respectively. Rates of NEDA-2 (no evidence of disease activity) ranged from 76% to 91% at 6 months of treatment with index DMTs and 66% to 84% at 12 months of treatment with index DMTs. Though limited by relatively short treatment duration with the index DMTs, our data suggest clinical and MRI benefit, as well as high rates of NEDA-2, in a large number of POMS patients, which can be used to guide future studies in this population.